• A breakthrough treatment for solid tumors, based on CAR-T cells with improved efficacy and safety
  • A collaboration of teams from leading Israeli institutions: Rambam Medical Center (Haifa), Ichilov-Sourasky Medical Center (Tel-Aviv) and  Weizmann Institute of Science (Rehovot)
  • Led by seasoned executives and R&D experts with proven track record
  • First in human indication: ovarian cancer – an unmet need with significant market
  • Awarded a non-dilutive grant by the Israel Innovation Authority (IIA)
  • The Need:

    There is huge anticipation for efficient solutions for treating solid tumors. Chimeric antigen receptor T (CAR-T) cells are T cells that have been genetically engineered to produce an artificial T cell receptor for use in Immunotherapy.

    Immunotherapy based on CAR-T cells has garnered significant excitement due to its success in treating hematological malignancies. However, solid tumors, the majority of cancer types, do not benefit from the technology, due to the inability of immune cells to infiltrate the solid tumor tissue.

  • Remission’s solution:

    Our scientists discovered that by silencing the expression of a certain gene in immune cells, the cells are becoming capable of efficiently infiltrating deeply into the tumor’s solid mass, resulting in efficient killing of cancer cells and reduced tumor volume.

  • First Indication: Ovarian Cancer – an unmet need

    Ovarian cancer is the fifth most common cause of cancer-related death among females in the US, with five-year survival rate of less than 25%, affecting 22,500 women each year.

    The ovarian cancer market valued at $1.8bn in 2018 and it is expected to grow to $6.7bn by 2028 with a CAGR of 14.4%.

    Remission is developing innovative CAR-T treatment specific to ovarian cancer with improved efficacy and reduced off-tumor interactions, thus increasing the product’s safety.

Skip to content